What's Happening?
Nabla, a pioneer in ambient clinical AI, has appointed Brian Manning as its new Chief Executive Officer. Manning, who previously served as President and CRO at Bamboo Health, brings over two decades of experience in expanding healthtech platforms. His
leadership at Bamboo Health saw the organization scale to over $140 million in annual recurring revenue and 300 employees. Manning's appointment is part of Nabla's strategy to enhance its enterprise go-to-market execution and global expansion. Co-founder and former CEO Alex LeBrun will transition to the role of Executive Chairman and Chief AI Officer, focusing on AI strategy and model development. Manning joins a leadership team that has already achieved significant commercial momentum, supporting over 100,000 clinicians nationwide and handling 40 million annual patient encounters.
Why It's Important?
The appointment of Brian Manning as CEO is a strategic move for Nabla as it seeks to solidify its position in the rapidly evolving healthcare AI sector. Manning's experience in scaling healthtech platforms is expected to drive Nabla's growth and expand its reach in the clinical AI market. This leadership change comes at a time when healthcare organizations are increasingly adopting AI technologies to improve patient care and operational efficiency. Manning's expertise in commercial strategy and his ability to pair commercial excellence with long-term vision are crucial for Nabla's ambition to become the preferred clinical AI partner for healthcare organizations globally.
What's Next?
Under Manning's leadership, Nabla is expected to accelerate its momentum and further establish itself in the healthcare AI industry. The company plans to expand its reach and enhance its product offerings to meet the growing demand for AI-driven healthcare solutions. Manning's focus will likely be on strengthening Nabla's market position and exploring new opportunities for collaboration and innovation. As healthcare enters a new era of AI, Nabla's leadership team will continue to build on its existing foundation and drive advancements in clinical intelligence.
